Acute myeloid leukemia and novel biological treatments: Monoclonal antibodies and cell-based gene-modified immune effectors

被引：19

作者：

Tettamanti, Sarah ^{[1
]}

Magnani, Chiara Francesca ^{[1
]}

Biondi, Andrea ^{[1
]}

Biagi, Ettore ^{[1
]}

机构：

[1] Univ Milano Bicocca, San Gerardo Hosp, Dept Pediat, Ctr Ric Matilde Tettamanti, I-20052 Monza, Italy

来源：

IMMUNOLOGY LETTERS | 2013年 / 155卷 / 1-2期

关键词：

Acute myeloid leukemia (AML); Monoclonal antibody (mAb); Chimeric antigen receptor (CAR); Cytokine-induced killer (CIK) cells; Immunotherapy; Gene therapy; INDUCED KILLER-CELLS; RECEPTOR-ALPHA CHAIN; GEMTUZUMAB-OZOGAMICIN; INDUCTION THERAPY; RANDOMIZED-TRIAL; EXPRESSION; ANTIGEN; RECOMMENDATIONS; MANAGEMENT; INFUSIONS;

D O I：

10.1016/j.imlet.2013.09.013

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

In the context of acute myeloid leukemia (AML) treatment, the interface between chemotherapy and immunotherapy is at present getting closer as never before. Scientific research is oriented in overcoming the main limits of actual chemotherapeutic regimens against AML, which still accounts for a considerable number of relapsed or resistant forms. A lot of investments have been done in the use of monoclonal antibodies (mAbs) and recently gene-modified immune cells have been considered as an alternative approach whenever chemotherapy fails to eradicate the disease. In this sense, AML is a potential suitable target for immunotherapeutic approaches, due to overexpression of several tumor antigens. Here we describe the state of the art of mAbs and cellular therapies employing engineered immune effectors, developed against specific AML antigens, in a window embracing preclinical research and translational studies to the clinical setting. (C) 2013 Elsevier B.V. All rights reserved.

引用

页码：43 / 46

页数：4

共 41 条

[1] T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE antibody construct [J].

Aigner, M. ;

Feulner, J. ;

Schaffer, S. ;

Kischel, R. ;

Kufer, P. ;

Schneider, K. ;

Henn, A. ;

Rattel, B. ;

Friedrich, M. ;

Baeuerle, P. A. ;

Mackensen, A. ;

Krause, S. W. .

LEUKEMIA, 2013, 27 (05) :1107-1115

[2] Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell [J].

Bonnet, D ;

Dick, JE .

NATURE MEDICINE, 1997, 3 (07) :730-737

[3] Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia [J].

Burnett, Alan K. ;

Russell, Nigel H. ;

Hills, Robert K. ;

Kell, Jonathan ;

Freeman, Sylvie ;

Kjeldsen, Lars ;

Hunter, Ann E. ;

Yin, John ;

Craddock, Charles F. ;

Dufva, Inge Hoegh ;

Wheatley, Keith ;

Milligan, Donald .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (32) :3924-3931

[4] Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years [J].

Candoni, Anna ;

Martinelli, Giovanni ;

Toffoletti, Eleonora ;

Chiarvesio, Alexia ;

Tiribelli, Mario ;

Malagola, Michele ;

Piccaluga, Pier Paolo ;

Michelutti, Angela ;

Simeone, Erica ;

Damiani, Daniela ;

Russo, Domenico ;

Fanin, Renato .

LEUKEMIA RESEARCH, 2008, 32 (12) :1800-1808

[5] Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study [J].

Castaigne, Sylvie ;

Pautas, Cecile ;

Terre, Christine ;

Raffoux, Emmanuel ;

Bordessoule, Dominique ;

Bastie, Jean-Noel ;

Legrand, Ollivier ;

Thomas, Xavier ;

Turlure, Pascal ;

Reman, Oumedaly ;

de Revel, Thierry ;

Gastaud, Lauris ;

de Gunzburg, Noemie ;

Contentin, Nathalie ;

Henry, Estelle ;

Marolleau, Jean-Pierre ;

Aljijakli, Ahmad ;

Rousselot, Philippe ;

Fenaux, Pierre ;

Preudhomme, Claude ;

Chevret, Sylvie ;

Dombret, Herve .

LANCET, 2012, 379 (9825) :1508-1516

[6]

Casucci M, 2013, BLOOD ASH

[7] Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel [J].

Creutzig, Ursula ;

van den Heuvel-Eibrink, Marry M. ;

Gibson, Brenda ;

Dworzak, Michael N. ;

Adachi, Souichi ;

de Bont, Eveline ;

Harbott, Jochen ;

Hasle, Henrik ;

Johnston, Donna ;

Kinoshita, Akitoshi ;

Lehrnbecher, Thomas ;

Leverger, Guy ;

Mejstrikova, Ester ;

Meshinchi, Soheil ;

Pession, Andrea ;

Raimondi, Susana C. ;

Sung, Lillian ;

Stary, Jan ;

Zwaan, Christian M. ;

Kaspers, Gertjan J. L. ;

Reinhardt, Dirk .

BLOOD, 2012, 120 (16) :3187-3205

[8] Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy [J].

Di Stasi, Antonio ;

Tey, Siok-Keen ;

Dotti, Gianpietro ;

Fujita, Yuriko ;

Kennedy-Nasser, Alana ;

Martinez, Caridad ;

Straathof, Karin ;

Liu, Enli ;

Durett, April G. ;

Grilley, Bambi ;

Liu, Hao ;

Cruz, Conrad R. ;

Savoldo, Barbara ;

Gee, Adrian P. ;

Schindler, John ;

Krance, Robert A. ;

Heslop, Helen E. ;

Spencer, David M. ;

Rooney, Cliona M. ;

Brenner, Malcolm K. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (18) :1673-1683

[9] Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet [J].

Doehner, Hartmut ;

Estey, Elihu H. ;

Amadori, Sergio ;

Appelbaum, Frederick R. ;

Buechner, Thomas ;

Burnett, Alan K. ;

Dombret, Herve ;

Fenaux, Pierre ;

Grimwade, David ;

Larson, Richard A. ;

Lo-Coco, Francesco ;

Naoe, Tomoki ;

Niederwieser, Dietger ;

Ossenkoppele, Gert J. ;

Sanz, Miguel A. ;

Sierra, Jorge ;

Tallman, Martin S. ;

Loewenberg, Bob ;

Bloomfield, Clara D. .

BLOOD, 2010, 115 (03) :453-474

[10] Stem cell gene expression programs influence clinical outcome in human leukemia [J].

Eppert, Kolja ;

Takenaka, Katsuto ;

Lechman, Eric R. ;

Waldron, Levi ;

Nilsson, Bjoern ;

van Galen, Peter ;

Metzeler, Klaus H. ;

Poeppl, Armando ;

Ling, Vicki ;

Beyene, Joseph ;

Canty, Angelo J. ;

Danska, Jayne S. ;

Bohlander, Stefan K. ;

Buske, Christian ;

Minden, Mark D. ;

Golub, Todd R. ;

Jurisica, Igor ;

Ebert, Benjamin L. ;

Dick, John E. .

NATURE MEDICINE, 2011, 17 (09) :1086-U91

← 1 2 3 4 5 →